[go: up one dir, main page]

PE20060314A1 - Prodrogas de estriol y estetrol - Google Patents

Prodrogas de estriol y estetrol

Info

Publication number
PE20060314A1
PE20060314A1 PE2005000555A PE2005000555A PE20060314A1 PE 20060314 A1 PE20060314 A1 PE 20060314A1 PE 2005000555 A PE2005000555 A PE 2005000555A PE 2005000555 A PE2005000555 A PE 2005000555A PE 20060314 A1 PE20060314 A1 PE 20060314A1
Authority
PE
Peru
Prior art keywords
sulfamoylbenzoate
ilo
trien
steroid
prodrogs
Prior art date
Application number
PE2005000555A
Other languages
English (en)
Inventor
Peter Droescher
Walter Elger
Alexander Hillisch
Gudrun Reddersen
Ralf Wyrwa
Sven Ring
Birgitt Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060314A1 publication Critical patent/PE20060314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A PRODROGAS DE ESTRIOL Y ESTEROL DE FORMULA (I), EN DONDE EL GRUPO Y ESTA UNIDO AL ESTEROIDE QUE DEBE SER LIBERADO, DONDE n ES DE 0 A 4; Y CUANDO R1, R2 O R3 ES INDEPENDIENTEMENTE -SO2NH2 O -NHSO2NH2, EL RESTO DE SUSTITUYENTES TOMAN EL VALOR DE H, FLUOR, Cl, OH O METOXI; R4, R16 Y R17, SON INDEPENDIENTEMENTE OH, TRIMETILSILILOXI, TER-BUTILDIMETILSILILOXI, BENZOATO, ENTRE OTROS; R15 ES PREFERENTEMENTE H; ESTEROIDE ES UN SISTEMA DE ANILLO ABCD DE FORULAS DE IIA A IID. SON COMPUESTOS PREFERIDOS: 3'-SULFAMOILBENZOATO DE 3,16*-DIHIDROXIESTRA-1,3,5(10)-TRIEN-17ß-ILO, 3'-SULFAMOILBENZOATO DE 3,17ß-DIHIDROXIESTRA-1,3,5(10)-TRIEN-16*-ILO, 4'-SULFAMOILBENZOATO DE 3,15*,17ß-TRIHIDROXIESTRA-1,3,5(10)-TRIEN-17ß-ILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMEINTO DE ELABORACION Y UNA COMPOSICION FARMACEUTICA QUE ADEMAS CONTIENE POR LO MENOS OTRO ESTEROIDE TAL COMO UN GESTAGENO COMO PROGESTERONA, NORETISTERONA, DIENOGEST, ENTRE OTROS. SIENDO UTIL PARA TERAPIA DE REEMPLAZO HORMONAL, TRATAMIENTO DE ENDOMETRIOSIS, CARCINOMA DE MAMA O PROSTATA, HIPOGONADISMO
PE2005000555A 2004-05-21 2005-05-20 Prodrogas de estriol y estetrol PE20060314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004025985A DE102004025985A1 (de) 2004-05-21 2004-05-21 Estriol- und Estetrol-Prodrugs

Publications (1)

Publication Number Publication Date
PE20060314A1 true PE20060314A1 (es) 2006-05-25

Family

ID=34969311

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000555A PE20060314A1 (es) 2004-05-21 2005-05-20 Prodrogas de estriol y estetrol

Country Status (11)

Country Link
EP (1) EP1747231A1 (es)
JP (1) JP2007538027A (es)
AR (1) AR049108A1 (es)
DE (1) DE102004025985A1 (es)
GT (1) GT200500120A (es)
PA (1) PA8633801A1 (es)
PE (1) PE20060314A1 (es)
SV (1) SV2006002122A (es)
TW (1) TW200612962A (es)
UY (1) UY28910A1 (es)
WO (1) WO2005113576A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
CN100396693C (zh) * 2006-11-08 2008-06-25 浙江大学 1,4-孕二烯-16β-甲基-17α,21-二羟基物的制备方法
CN102079771B (zh) * 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1238739A (fr) * 1958-08-04 1960-08-19 Chimiotherapie Lab Franc Procédé de préparation de dérivés hydrosolubles de testostérone
FR8290M (es) * 1968-12-31 1970-11-09 Rech Chimiques Et Ind Mar Lab
US5001234A (en) * 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
DE19712488A1 (de) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
EP1284272A4 (en) * 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TWI331154B (en) * 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs

Also Published As

Publication number Publication date
SV2006002122A (es) 2006-05-09
TW200612962A (en) 2006-05-01
DE102004025985A1 (de) 2005-12-15
JP2007538027A (ja) 2007-12-27
EP1747231A1 (de) 2007-01-31
PA8633801A1 (es) 2006-03-24
AR049108A1 (es) 2006-06-28
UY28910A1 (es) 2005-12-30
GT200500120A (es) 2006-01-24
WO2005113576A1 (de) 2005-12-01

Similar Documents

Publication Publication Date Title
RU2221569C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНДРОСТ-5-ЕН-3-β, 17β -ДИОЛ, И ЕГО ИСПОЛЬЗОВАНИЕ
PH30747A (en) Combination therapy for the treatment of estrogen sensitive disease.
BRPI0516243B8 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
KR970701039A (ko) 성 스테로이드를 함유하는 경피 치료 시스템(Sexual Steroid-Containing Transdermal Therapeutic Systems)
DE69434697D1 (de) Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose
WO2001068074A3 (en) Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
BR0114801A (pt) Composto modulador receptor de androgênio seletivo de tecido, composição, composição farmacêutica, método para a ligação de um composto modulador receptor de androgênio seletivo a um receptor de androgênio, método para a modulação da espermatogênese em um indivìduo, método de terapia hormonal, método para o tratamento para um indivìduo tendo uma condição relacionada a um hormÈnio, método para o tratamento para um indivìduo tendo c‰ncer prostático e método para a determinação da presença de um composto
WO1999063974A3 (en) Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
RU2001101492A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНДРОСТ-5-EH-3-β, 17β-ДИОЛ, И ЕГО ИСПОЛЬЗОВАНИЕ
NO20090578L (no) Farmasoytisk sammensetning inneholdende en tetrahydrofolsyre
CR8800A (es) Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona
JP4716726B2 (ja) 新しいエトノゲストレルエステル
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
WO2001003687A3 (en) Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans
CA2431645A1 (en) Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
PE20060314A1 (es) Prodrogas de estriol y estetrol
WO2004006936A8 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
SE0400346D0 (sv) Steroids for cancer treatment
RU2009102772A (ru) 18-метил-19-норандрост-4-ен-17, 17-спироэфир (18-метил-19-нор-20-спирокс-4-ен-3-он) и фармацевтические препараты, которые его содержат
RU2001101892A (ru) Производное тестостерона
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
BR0108411A (pt) Formulação contraceptiva masculina compreendendo noretisterona

Legal Events

Date Code Title Description
FC Refusal